Cargando…

Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer

OBJECTIVE: This study aimed to identify patients at a high risk of recurrence using preoperative high-resolution computed tomography (HRCT) in clinical stage I non-small cell lung cancer (NSCLC). METHODS: A total of 567 patients who underwent screening and 1,216 who underwent external validation for...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsutani, Yasuhiro, Shimada, Yoshihisa, Ito, Hiroyuki, Miyata, Yoshihiro, Ikeda, Norihiko, Nakayama, Haruhiko, Okada, Morihito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215653/
https://www.ncbi.nlm.nih.gov/pubmed/34164334
http://dx.doi.org/10.3389/fonc.2021.622742
_version_ 1783710282986553344
author Tsutani, Yasuhiro
Shimada, Yoshihisa
Ito, Hiroyuki
Miyata, Yoshihiro
Ikeda, Norihiko
Nakayama, Haruhiko
Okada, Morihito
author_facet Tsutani, Yasuhiro
Shimada, Yoshihisa
Ito, Hiroyuki
Miyata, Yoshihiro
Ikeda, Norihiko
Nakayama, Haruhiko
Okada, Morihito
author_sort Tsutani, Yasuhiro
collection PubMed
description OBJECTIVE: This study aimed to identify patients at a high risk of recurrence using preoperative high-resolution computed tomography (HRCT) in clinical stage I non-small cell lung cancer (NSCLC). METHODS: A total of 567 patients who underwent screening and 1,216 who underwent external validation for clinical stage I NSCLC underwent lobectomy or segmentectomy. Staging was used on the basis of the 8(th) edition of the tumor–node–metastasis classification. Recurrence-free survival (RFS) was estimated using the Kaplan–Meier method, and the multivariable Cox proportional hazards model was used to identify independent prognostic factors for RFS. RESULTS: A multivariable Cox analysis identified solid component size (hazard ratio [HR], 1.66; 95% confidence interval [CI] 1.30–2.12; P < 0.001) and pure solid type (HR, 1.82; 95% CI 1.11–2.96; P = 0.017) on HRCT findings as independent prognostic factors for RFS. When patients were divided into high-risk (n = 331; solid component size of >2 cm or pure solid type) and low-risk (n = 236; solid component size of ≤2 cm and part solid type) groups, there was a significant difference in RFS (HR, 5.33; 95% CI 3.09–9.19; 5-year RFS, 69.8% vs. 92.9%, respectively; P < 0.001). This was confirmed in the validation set (HR, 5.32; 95% CI 3.61–7.85; 5-year RFS, 72.0% vs. 94.8%, respectively; P < 0.001). CONCLUSIONS: In clinical stage I NSCLC, patients with a solid component size of >2 cm or pure solid type on HRCT were at a high risk of recurrence.
format Online
Article
Text
id pubmed-8215653
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82156532021-06-22 Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer Tsutani, Yasuhiro Shimada, Yoshihisa Ito, Hiroyuki Miyata, Yoshihiro Ikeda, Norihiko Nakayama, Haruhiko Okada, Morihito Front Oncol Oncology OBJECTIVE: This study aimed to identify patients at a high risk of recurrence using preoperative high-resolution computed tomography (HRCT) in clinical stage I non-small cell lung cancer (NSCLC). METHODS: A total of 567 patients who underwent screening and 1,216 who underwent external validation for clinical stage I NSCLC underwent lobectomy or segmentectomy. Staging was used on the basis of the 8(th) edition of the tumor–node–metastasis classification. Recurrence-free survival (RFS) was estimated using the Kaplan–Meier method, and the multivariable Cox proportional hazards model was used to identify independent prognostic factors for RFS. RESULTS: A multivariable Cox analysis identified solid component size (hazard ratio [HR], 1.66; 95% confidence interval [CI] 1.30–2.12; P < 0.001) and pure solid type (HR, 1.82; 95% CI 1.11–2.96; P = 0.017) on HRCT findings as independent prognostic factors for RFS. When patients were divided into high-risk (n = 331; solid component size of >2 cm or pure solid type) and low-risk (n = 236; solid component size of ≤2 cm and part solid type) groups, there was a significant difference in RFS (HR, 5.33; 95% CI 3.09–9.19; 5-year RFS, 69.8% vs. 92.9%, respectively; P < 0.001). This was confirmed in the validation set (HR, 5.32; 95% CI 3.61–7.85; 5-year RFS, 72.0% vs. 94.8%, respectively; P < 0.001). CONCLUSIONS: In clinical stage I NSCLC, patients with a solid component size of >2 cm or pure solid type on HRCT were at a high risk of recurrence. Frontiers Media S.A. 2021-06-07 /pmc/articles/PMC8215653/ /pubmed/34164334 http://dx.doi.org/10.3389/fonc.2021.622742 Text en Copyright © 2021 Tsutani, Shimada, Ito, Miyata, Ikeda, Nakayama and Okada https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Tsutani, Yasuhiro
Shimada, Yoshihisa
Ito, Hiroyuki
Miyata, Yoshihiro
Ikeda, Norihiko
Nakayama, Haruhiko
Okada, Morihito
Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer
title Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer
title_full Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer
title_fullStr Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer
title_full_unstemmed Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer
title_short Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer
title_sort identification of high-risk of recurrence in clinical stage i non-small cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215653/
https://www.ncbi.nlm.nih.gov/pubmed/34164334
http://dx.doi.org/10.3389/fonc.2021.622742
work_keys_str_mv AT tsutaniyasuhiro identificationofhighriskofrecurrenceinclinicalstageinonsmallcelllungcancer
AT shimadayoshihisa identificationofhighriskofrecurrenceinclinicalstageinonsmallcelllungcancer
AT itohiroyuki identificationofhighriskofrecurrenceinclinicalstageinonsmallcelllungcancer
AT miyatayoshihiro identificationofhighriskofrecurrenceinclinicalstageinonsmallcelllungcancer
AT ikedanorihiko identificationofhighriskofrecurrenceinclinicalstageinonsmallcelllungcancer
AT nakayamaharuhiko identificationofhighriskofrecurrenceinclinicalstageinonsmallcelllungcancer
AT okadamorihito identificationofhighriskofrecurrenceinclinicalstageinonsmallcelllungcancer